Donatella Grasso

706 total citations
22 papers, 159 citations indexed

About

Donatella Grasso is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, Donatella Grasso has authored 22 papers receiving a total of 159 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 7 papers in Cancer Research and 4 papers in Surgery. Recurrent topics in Donatella Grasso's work include Cancer Treatment and Pharmacology (6 papers), Breast Cancer Treatment Studies (6 papers) and HER2/EGFR in Cancer Research (5 papers). Donatella Grasso is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Breast Cancer Treatment Studies (6 papers) and HER2/EGFR in Cancer Research (5 papers). Donatella Grasso collaborates with scholars based in Italy, Portugal and Australia. Donatella Grasso's co-authors include Marco Danova, Alberto Riccardi, Silvia Brugnatelli, Tania Perrone, Elisabetta Gattoni, Valentina Sini, Francesca Poggio, Arlindo R. Ferreira, Elena Poletto and Emanuela Risi and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and European Journal of Cancer.

In The Last Decade

Donatella Grasso

19 papers receiving 154 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Donatella Grasso Italy	9	107	40	29	26	25	22	159
Yuriko N. Koyanagi Japan	9	88 0.8×	25 0.6×	56 1.9×	42 1.6×	22 0.9×	18	178
Gianmarco Leone Italy	8	84 0.8×	101 2.5×	31 1.1×	30 1.2×	24 1.0×	20	193
Tatiana Hadjieva Bulgaria	5	47 0.4×	61 1.5×	26 0.9×	19 0.7×	18 0.7×	7	154
Bruno Chiurazzi Italy	5	50 0.5×	24 0.6×	23 0.8×	31 1.2×	6 0.2×	12	118
Nicholas Venturini United States	5	87 0.8×	53 1.3×	13 0.4×	42 1.6×	21 0.8×	9	164
S Kudoh Japan	7	95 0.9×	99 2.5×	34 1.2×	95 3.7×	17 0.7×	9	214
Mary Kay Barton Canada	9	69 0.6×	49 1.2×	27 0.9×	40 1.5×	35 1.4×	40	196
Nadia Raban France	7	62 0.6×	21 0.5×	23 0.8×	43 1.7×	22 0.9×	17	145
Carmen Salvador Coloma Spain	9	116 1.1×	82 2.0×	21 0.7×	71 2.7×	71 2.8×	32	248
Elda Lamaj Italy	7	53 0.5×	20 0.5×	7 0.2×	62 2.4×	9 0.4×	12	159

Countries citing papers authored by Donatella Grasso

Since Specialization

Citations

This map shows the geographic impact of Donatella Grasso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donatella Grasso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donatella Grasso more than expected).

Fields of papers citing papers by Donatella Grasso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donatella Grasso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donatella Grasso. The network helps show where Donatella Grasso may publish in the future.

Co-authorship network of co-authors of Donatella Grasso

This figure shows the co-authorship network connecting the top 25 collaborators of Donatella Grasso. A scholar is included among the top collaborators of Donatella Grasso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donatella Grasso. Donatella Grasso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Caputo, Roberta, Alessandra Fabi, Emanuela Romagnoli, et al.. (2022). Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 Trial. Breast Cancer Targets and Therapy. Volume 14. 351–362.

2.

Arpino, Grazia, Giampaolo Bianchini, Luca Malorni, et al.. (2022). Circulating tumor DNA (ctDNA) and serum thymidine kinase 1 activity (TKa) matched dynamics in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor 2–negative (HER2-) advanced breast cancer (ABC) treated in first-line (1L) with ribociclib (RIB) and letrozole (LET) in the BioItaLEE trial.. Journal of Clinical Oncology. 40(16_suppl). 1012–1012. 4 indexed citations

3.

Martinelli, Valentina, Alberta Ferrari, Carlos A. Garcia‐Etienne, et al.. (2019). “My Husband Affects Me More Than My Cancer”: Reflections on Simultaneous Intimate Partner Violence and Breast Cancer Experience in a 48-Year-Old Woman. Journal of Cancer Education. 35(5). 1041–1045. 8 indexed citations

4.

Garcia‐Etienne, Carlos A., Alberta Ferrari, Donatella Grasso, et al.. (2019). The institution of a Multi‐disciplinary Italian Breast Unit: Reflections of the first psychosocial research study results on distress and quality of life. The Breast Journal. 25(4). 678–681. 3 indexed citations

5.

Bernardo, Antônio, Raffaella Palumbo, Rebecca Pedersini, et al.. (2017). Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials. Clinical Breast Cancer. 17(6). 433–440. 6 indexed citations

6.

Lambertini, Matteo, Arlindo R. Ferreira, Antonio Di Meglio, et al.. (2017). Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study. Clinical Breast Cancer. 17(8). 601–610.e2. 25 indexed citations

7.

Rovati, B., S. Mariucci, Sara Delfanti, et al.. (2016). Simultaneous detection of circulating immunological parameters and tumor biomarkers in early stage breast cancer patients during adjuvant chemotherapy. Cellular Oncology. 39(3). 211–228. 7 indexed citations

8.

Lambertini, Matteo, Arlindo R. Ferreira, Francesca Poggio, et al.. (2015). Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. The Oncologist. 20(8). 880–889. 22 indexed citations

9.

Cazzaniga, Marina Elena, Edda Simoncini, Carlo Tondini, et al.. (2015). 1872 Moving beyond clinical trials: A real word multicenter Italian experience with albumin-bounded Paclitaxel (nab-Paclitaxel) in metastatic breast cancer. European Journal of Cancer. 51. S290–S290. 1 indexed citations

10.

Pedrazzoli, Paolo, Giovanni Martinelli, Alessandro M. Gianni, et al.. (2014). Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry. Biology of Blood and Marrow Transplantation. 20(4). 501–506. 6 indexed citations

11.

Brugnatelli, Silvia, et al.. (2011). Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients.. PubMed. 97(3). 362–6. 12 indexed citations

12.

Brugnatelli, Silvia, et al.. (2011). Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients. Tumori Journal. 97(3). 362–366. 11 indexed citations

13.

Travaglino, Erica, Valentina Matti, Donatella Grasso, et al.. (2010). Studio degli effetti biologici della somministrazione del fattore di crescita granulocitario peghilato (PEGFILGRASTIM) sui granulociti neutrofili circolanti di pazienti affette da carcinoma mammario trattate con schemi di chemioterapia dose-dense. Università degli Studi di Pavia. 122(2). 313–334.

14.

Delfanti, Sara, B. Rovati, Donatella Grasso, et al.. (2009). Chemotherapy-induced anemia in breast cancer patients treated with pegfilgrastim-supported dose-dense regimens. Clinical and Experimental Medicine. 10(2). 135–138. 3 indexed citations

15.

Invernizzi, Rosangela, Donatella Grasso, Erica Travaglino, et al.. (2008). Biological Effects of Pegfilgrastim on Circulating Neutrophils in Breast Cancer Patients Undergoing Dose-Dense Chemotherapy. Oncology. 75(3-4). 237–244. 9 indexed citations

16.

Danova, Marco, et al.. (2007). In vivo biological effects of pegfilgrastim after myelosuppressive chemotherapy in breast cancer.. PubMed. 27(5A). 3399–402. 3 indexed citations

17.

Riccardi, Alberto, Silvia Brugnatelli, Marco Danova, et al.. (2006). Weekly Docetaxel and Gemcitabine following Docetaxel plus Epirubicin or Vinorelbine as First-Line Treatment of Metastatic Breast Cancer: Results of a Multicenter Phase II Study. Tumori Journal. 92(1). 6–12. 5 indexed citations

18.

Riccardi, Alberto, Donatella Grasso, & Marco Danova. (2003). Bisphosphonates in Oncology: Physiopathologic Bases and Clinical Activity. Tumori Journal. 89(3). 223–236. 11 indexed citations

19.

Riccardi, Alberto, Carmine Tinelli, Camillo Porta, et al.. (2002). Response to first-line chemotherapy and long-term survival in patients with multiple myeloma. European Journal of Cancer. 39(1). 31–37. 13 indexed citations

20.

Riccardi, Alberto, Marco Danova, Silvia Brugnatelli, et al.. (2001). A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01). British Journal of Cancer. 85(2). 141–146. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact